Merck & Co., Inc. (LON:MRK)

Market Cap	224.91B +24.1%
Revenue (ttm)	48.30B +1.3%
Net Income	13.56B +6.6%
EPS	5.41 +8.0%
Shares Out	n/a
PE Ratio	16.58
Forward PE	23.82
Dividend	n/a
Ex-Dividend Date	n/a

Volume	17,206
Average Volume	168,215
Open	47.00
Previous Close	46.00
Day's Range	46.50 - 47.00
52-Week Range	42.00 - 63.00
Beta	0.67
RSI	55.82
Earnings Date	Feb 3, 2026

About Merck & Co.

Merck & Co., Inc. operates as a healthcare company worldwide. The company offers human health pharmaceutical for various areas under the Keytruda, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, RotaTeq, Pneumovax 23, Bridion, Dificid, Zerbaxa, Noxafil, Winrevair, Adempas, Verquvo, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. It also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, B...

• Industry: Specialty Retail
• Sector: Consumer Discretionary
• Founded: 1891
• Employees: 74,000
• Stock Exchange: London Stock Exchange
• Ticker Symbol: MRK

Financial Performance

In 2025, Merck & Co.'s revenue was $65.01 billion, an increase of 1.31% compared to the previous year's $64.17 billion. Earnings were $18.25 billion, an increase of 6.64%.

Financial numbers in USD